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Continuing Education

Acute Coronary Syndromes: Current Treatment Guidelines and Updates

by Bernard Lau, Pharm.D. Candidate 2014, Michael Lee, Pharm.D. Candidate 2014, Thien Tran, Pharm.D. Candidate 2014, Laura
Tsu, Pharm.D, Midwestern University College of Pharmacy-Glendale
Goal:
This home-study CPE activity has been
developed to educate pharmacists on acute
coronary syndrome (ACS) and its medical
management.
Objectives: At the conclusion of this CPE
activity, successful participants should be
able to:
1. Identify the type of ACS (STEMI,
NSTEMI, or UA) based on imaging
and laboratory values.
2. List the recommendations for
emergency department management
for ACS.
3. Assess the eligibility of patients
(STEMI or NSTEMI/UA) for PCI or
fibrinolytic therapy.
4. Develop an appropriate
pharmacotherapy treatment plan in
patients admitted into hospital with
ACS (STEMI or NSTEMI/UA).
5. Discuss the medication management
for discharge in the patient with ACS.
Introduction
Cardiovascular disease (CVD) is a
major leading cause of death worldwide.
Acute coronary syndromes (ACS)
make up the majority of CVD related
mortalities, with more than 1.2 million
Americans suffering from some sort of
ACS every year.1 ACS, a result of having
coronary heart disease, is very costly to
health care and the economy, with direct
and indirect costs totaling more than
$177 billion in 2010.
Etiology
ACS is a result of occlusion and
rupturing of atherosclerotic plaques in the
vasculature of the heart.1 Atherosclerosis
is a narrowing of the arteries that involves
excess cholesterol and inflammation. The
initial stage of this disease begins with
an atherosclerotic plaque, or atheroma.
These plaques normally occur in humans
starting in the adolescent years. They
are composed of macrophages that have
taken up oxidized low density lipoproteins
(LDL). Over time, these macrophages
become foam cells, which subsequently
become calcified as they become older and
less metabolically active. The calcified
plaque causes the artery to become stiff,
which induces more stress on the arteries
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when blood flows through them as they
are less compliant. As a result, gene
regulation is altered and the endothelial
cells lining the blood vessels decrease
their production of nitric oxide, a potent
endogenous vasodilator. The alteration
in gene regulation also causes an increase
in the rate of oxidation of LDL and
enables them to enter the arterial wall.
Monocytes also become more adhesive
to the arterial wall, which causes smooth
cell proliferation and the release of local
vasoconstrictors and prothrombotic
substances into the blood, resulting in an
inflammatory response.
Pathophysiology
The leading cause of ACS in most
patients is rupture of an unstable
atherosclerotic plaque with subsequent
thrombus development resulting in the
limitation or interruption of coronary
blood flow.1 In contrast to a stable plaque,
an unstable plaque has an irregular shape,
a thin fibrous cap, minimal amount of
smooth muscle cells and a large lipid core
that is highly populated with inflammatory
cells such as macrophages and
lymphocytes. These inflammatory cells
release proteolytic enzymes and cause
the thinning of the fibrous cap resulting
in a plaque that is more susceptible to
tear under constant shear stress. It is
also noted that plaques that occlude less
than 50% of the diameter of the coronary
artery are more likely to rupture than
those with a higher degree of occlusion.
Following plaque rupture, tissue factor and
subendothelial collagen are exposed to the
blood components at the site of rupture,
leading to platelet adhesion and activation.
Activated platelets release thromboxane
A2, adenosine diphosphate (ADP), and
other vasoactive and prothrombotic
substances that further intensify
platelet recruitment and aggregation.
Additionally, during platelet activation,
ADP binds to the P2Y12 receptors and
induces a conformational change in the
glycoprotein (GP) IIb/IIIa receptors
located on the surface of platelets, thereby
facilitating the binding of fibrinogens
responsible for cross-linking other
platelets to form a preliminary clot. At
the same time, the extrinsic coagulation
cascade pathway is also activated by the

exposed tissue elements at the site of
injury. Thrombin (factor IIa), the final
product of this cascade and a potent
platelet aggregation agonist, stabilizes
the cross-linked platelets by converting
the fibrinogen bridges to fibrin, thus
trapping the red blood cells to form a
stable clot. Other clotting factors also
contribute to clot extension by gathering
on the anionic surface of activated
platelets and promoting more thrombin
production. When a thrombus causes
complete occlusion of the coronary artery
and interruption of coronary blood flow,
myocardial ischemia occurs and may
lead to necrosis of myocardial tissues
(i.e. myocardial infarction or MI). Most
ACS cases involve only one ruptured
atherosclerotic plaque in a major coronary
artery; however, multiple ruptured plaques
can occur and may affect more than
one coronary artery. ACS patients with
multiple coronary artery involvement
usually have a worse prognosis.
Types of ACS
The spectrum of ACS encompasses
all clinical syndromes related to acute
myocardial ischemia as a result of an
imbalance between the oxygen supply
and demand in the myocardium.1 As
mentioned before, the disruption of
oxygen balance is primarily due to
diminished myocardial blood flow
secondary to one or more occlusive
or partially occlusive coronary artery
thrombi. The types of ACS are ST
segment elevation myocardial infarction
(STEMI), non-ST segment elevation
myocardial infarction (NSTEMI), and
unstable angina (UA). They are classified
according to the electrocardiogram (ECG)
and cardiac chemical biomarkers. In
STEMI, the coronary artery thrombus is
completely occlusive and the ST segment
on the ECG is elevated. In both NSTEMI
and UA, the coronary artery thrombus is
partially occlusive and the ST segment
on the ECG is depressed or the T wave is
inverted. In order to differentiate between
NSTEMI from UA, the level of cardiac
biomarkers of myocardial necrosis such
as troponin I or T, or creatine kinase
myocardial band (CK-MB) are obtained
from a blood test. NSTEMI differs from
UA in that the extent of ischemia is
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usually severe enough to cause myocardial
necrosis, resulting in the subsequent
release of biomarkers from the damaged
tissues into the bloodstream. Therefore,
elevated level of cardiac biomarkers is
often seen in NSTEMI but not in UA.
Diagnosis & Clinical Presentations
Patients typically present to the
emergency department with chest pain
greater than 20 minutes that radiates to
shoulder, left arm, back, or jaw.1 Atypical
symptoms that can also be seen in patients
include nausea and vomiting, diaphoresis,
and shortness of breath. These atypical
symptoms are more common in women,
diabetics, and the elderly. A 12-lead
ECG should be obtained and interpreted
within 10 minutes of presentation to the
emergency department with ischemic
symptoms. Upon reviewing the findings
on the ECG, patients are either classified
as having STEMI or NSTEMI/UA, or
their complaint may be due to a noncardiac issue. Since myocardial ischemia
in some parts of the heart may not be
detected on the surface by the ECG, it is
important to review the ECG along with
the cardiac biomarkers. Following the
onset of myocardial ischemia, an increase
in troponin and CK-MB level in the
blood can be detected. One set of cardiac
biomarkers obtained in the emergency
department is often not long enough to
detect any changes in the level of the
cardiac biomarkers. Therefore, three sets
of cardiac biomarkers are usually obtained
6 to 8 hours apart to avoid a false negative
result. Further workup and individual
patient risk assessment should be included
in the definitive diagnosis of ACS.
ACS Treatment
Because time is crucial in stopping
the expansion of infarction and tissue
death in ACS patients, early treatment
goals involves timely restoration of blood
supply to the occluded artery in both
STEMI and NSTEMI patients, and in
the case of UA, prevention of complete
occlusion and MI.1 Other short-term goals
include symptom relief and prevention of
other MI complications, recurrent MI, and
death.
General treatment approaches for
all STEMI and intermediate to high
risk NSTEMI or UA patients include
hospital admission, continuous ECG
and vital signs monitoring, glycemic
control, pain relief, and bed rest.1 Upon

emergency department arrival, MONA
therapy (see below), and beta-blocker
therapy if not contraindicated, should be
initiated immediately for all ACS patients.
Patients should be triaged by ACS type
as determined from ECG and laboratory
findings, after which subsequent treatment
plan is chosen based on individual
patient’s signs and symptoms and past
medical history.
Initial treatment (MONA therapy plus
Beta-blocker)
Initial treatment of ACS patients
involves the MONA therapy, which stands
for Morphine, Oxygen, Nitroglycerin,
and Aspirin. Beta-blockers should also
be given to patients if not contraindicated
with one or more of the following: 1) signs
of heart failure, 2) evidence of low cardiac
output, 3) increased risk of cardiogenic
shock, 4) second or third degree heart
block, or 5) active asthma or reactive
airway disease.2,3 Intravenous morphine
is administered as an analgesic to patients
who continue to have pain refractory to
nitroglycerin and also acts as a vasodilator
to reduce preload. Oxygen is administered
by nasal cannula to patients with oxygen
saturation less than 90% for no more
than 6 hours. For patients who do not
appear at risk of hypoxemia or respiratory
distress, excessive use beyond 6 hours
can lead to systemic vasoconstriction,
and high flow rates can be harmful to
patients with chronic obstructive airway
disease.2,3 Nitroglycerin is administered
as continuous IV infusion if patients
have continued chest pain, and should be
titrated to pain relief. However, there are
contraindications to the use of nitrates
in patients presenting to emergency
department with hypotension, marked
bradycardia or tachycardia, MI in the right
side of the heart, documented use of a
phosphodiesterase type 5 inhibitor such as
sildenafil or vardenafil within 24 hours or
tadalafil within 48 hours. Enteric-coated
aspirin must be chewed and swallowed
immediately to break the enteric coating
to achieve rapid platelet inhibition.
Non-enteric coated formulations may be
used for more rapid buccal absorption.2,3
Beta-blockers should be administered
orally early in hospitalization and continue
indefinitely to help reduce heart rate, blood
pressure, and myocardial contractility.
The use of beta-blocker can reduce the
risk of recurrent ischemia, infarct size,
and ventricular arrhythmias following

MI. Cardioselective beta-blockers, such
as metoprolol and atenolol, are commonly
used, but are not required. IV betablockers are no longer recommended
routinely due to a high risk of cardiogenic
shock.2,3
Pharmacologic agents for in-hospital
management of ACS
Once the patients have been stabilized
with MONA therapy, proper treatment
for their specific ACS condition needs to
be initiated. Drugs used in this process
include anticoagulants, antiplatelets,
and fibrinolytics. We will outline the
mechanism of action and monitoring
parameters of these agents prior to
discussing each agent’s place in therapy.
Anticoagulant Agents
Anticoagulants essentially inactivate
clotting factors to prevent thrombus
formation and extension.2,3 The
anticoagulant agents that are commonly
used in the treatment of ACS include
unfractionated heparin (UFH), enoxaparin,
fondaparinux, bivalirudin, and warfarin.
UFH inhibits both factor IIa (thrombin)
and factor Xa with equal selectivity.2,3 The
dose is adjusted according to activated
clotting time (ACT) or activated partial
thromboplastin time (aPTT), but initial
dose adjustment for renal or hepatic
dysfunction is not required. Some
contraindications to therapy include active
bleeding, a history of heparin-induced
thrombocytopenia (HIT), risk of severe
bleeding, and recent stroke. The major
side effect is bleeding. When the patient
is on UFH, the monitoring parameters
are bedside monitoring of ACT or aPTT,
platelet count, and signs and symptoms of
active bleeding.2,3
Enoxaparin (Lovenox) is a low
molecular weight heparin (LMWH)
that inhibits factor Xa more strongly
than factor IIa.3 Dose reduction is
required ifcreatinine clearance (CrCl)
< 30 mL/min, and it is to be avoided
completely if CrCl < 15 mL/min. Some
contraindications include active bleeding,
history of HIT, risk of severe bleeding,
and recent stroke. The major side effects
are bleeding and bruising. Monitoring
parameters for enoxaparin include serum
creatinine, platelet count, and signs and
symptoms of bleeding. An advantage of
using enoxaparin over UFH is that it can
be administered subcutaneously.
Fondaparinux (Arixtra) is a synthetic
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pentasaccharide that selectively
inhibits factor Xa.3 Dose adjustment
is not required for renal or hepatic
impairment, but the use of fondaparinux
is contraindicated if CrCl < 30 mL/min.
Other contraindications are active bleeding
and risk of severe bleeding. Furthermore,
it has an increased risk of catheter
thrombosis if used as monotherapy.
When the patient is on fondaparinux, the
monitoring parameters include serum
creatinine and bleeding.
Bivalirudin (Angiomax) is a direct
thrombin inhibitor that specifically
targets thrombin.3 Dose reduction is
required for severe renal impairment,
and contraindications are active bleeding
and risk of severe bleeding. Also, it has
an increased risk of stent thrombosis.
Monitoring parameters include serum
creatinine and signs and symptoms of
bleeding. Bivalirudin monotherapy
has a lower risk of bleeding than
the combination therapy of UFH or
enoxaparin with GP IIb/IIIa inhibitors.
However, the combination of bivalirudin
with GP IIb/IIIa inhibitors has a higher
risk of bleeding without a corresponding
increase in efficacy, and therefore is not
recommended to use the combination of
bivalirudin and GP IIb/IIIa inhibitors.
Warfarin, a vitamin K antagonist,
reduces thrombus formation by inhibiting
the activation of vitamin K-dependent
clotting factors.1 The dose is adjusted
to maintain a target international
normalized ratio (INR) of 2 to 3. Some
contraindications include active bleeding,
risk of severe bleeding, pregnancy (except
in pregnant women with mechanical heart
valves)and uncontrolled hypertension.
The major side effect is bleeding. When
the patient is on warfarin, the monitoring
parameters are INR and signs and
symptoms of bleeding. Warfarin is not
commonly used as monotherapy in ACS
and should be prescribed for patients with
certain indications for warfarin, such as
atrial fibrillation, left ventricular thrombus,
and mechanical prosthetic heart valves.
Antiplatelet Agents
Aspirin (ASA)
ASA irreversibly inhibits
cyclooxygenase-1 (COX-1) and COX-2
enzymes which prevents the formation of
prostaglandin derivative, thromboxane-A,
thereby inhibiting platelet aggregation.1
Dose adjustment is not required for
renal or hepatic impairment, but avoid
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using ASA if CrCl < 10 mL/min or
in patient with severe liver disease.
Some contraindications are active
bleeding, hemophilia, severe untreated
hypertension, an active peptic ulcer, or
another serious source of gastrointestinal
or genitourinary bleeding. The major
side effect is gastrointestinal bleeding. It
is the preferred antiplatelet agent in all
ACS scenarios. It should be administered
to patients within 24 hours of hospital
admission. The patients will be on ASA
therapy indefinitely regardless of the type
of ACS.
Glycoprotein IIb/IIIa Inhibitors
GP IIb/IIIa inhibitors bind to the GP IIb/
IIIa receptors on the platelet preventing
platelet aggregation and thrombus
formation.3 The GP IIb/IIIa inhibitors that
are used in the treatment of ACS include
abciximab, eptifibitide, and tirofiban.2,3
Abciximab (ReoPro) does not
require dose adjustment for renal
or hepatic impairment.2,3 Some
contraindications include active bleeding,
thrombocytopenia, prior stroke and severe
uncontrolled hypertension. Abciximab,
being a monoclonal antibody, has a risk
of immune-mediated thrombocytopenia,
which can be treated with platelet
transfusions as needed for control of
bleeding. The major side effect of
abciximab is bleeding, so the main
monitoring parameters include signs and
symptoms of bleeding and platelet counts.
Eptifibitide (Integrillin) requires
dose reduction by 50% in patients
with CrCl < 50mL/min.2,3 Some
contraindications include active bleeding,
thrombocytopenia, prior stroke, renal
dialysis and severe uncontrolled
hypertension. Patients can be treated
with platelet transfusions as needed
to control bleeding due to a risk of
thrombocytopenia. The major side effect
with eptifibatide is bleeding. Monitoring
parameters for this drug include signs and
symptoms of bleeding, serum creatinine,
and platelet counts.
Tirofiban (Aggrastat) requires dose to
be reduced by 50% in patients with CrCl
< 30mL/min.2,3 Some contraindications
are active bleeding, thrombocytopenia,
prior stroke and severe uncontrolled
hypertension. Patients can be treated with
platelet transfusions as needed to control
bleeding due to risk of thrombocytopenia.
The major side effect is bleeding.
Monitoring parameters for this drug

include signs and symptoms of bleeding,
serum creatinine, and platelet counts.
P2Y12 receptor antagonists
P2Y12 receptor antagonists block
the P2Y12 receptors on platelets which
prevents activation of the GP IIb/IIIa
receptor complex, thereby reducing
platelet aggregation.3 The P2Y12 receptor
antagonists that are used in the treatment
of ACS include clopidogrel, prasugrel, and
ticagrelor.2,4
Clopidogrel (Plavix) is the most
frequently prescribed P2Y12 receptor
antagonist. An advantage of clopidogrel
is that it does not require dose adjustment
for renal or hepatic impairment.2,3 It
has a Black Box Warning against its
use in patients who are poor CYP2C19
metabolizers. This is because clopidogrel
is a prodrug that requires a two-step
conversion to an active metabolite, and
the effectiveness of the drug is dependent
on its activation to an active metabolite by
CYP2C19. Poor CYP2C19 metabolism
results in a smaller antiplatelet effect
and an increased risk of cardiovascular
events. Some contraindications are
hypersensitivity to clopidogrel, active
bleeding, and risk of severe bleeding. The
major side effect is bleeding.
Prasugrel (Effient) also does not require
dose adjustment for renal or hepatic
impairment.2,4 It is also a prodrug, but
it requires only a one-step conversion to
active metabolite. Some contraindications
with prasugrel include history of transient
ischemic attack (TIA), stroke, and active
bleeding. It has a FDA-labeled warning
against its use in patients greater than 75
years old or with a weight less than 60kg
due to concerns of an increased risk of
fatal and intracranial bleeding. Prasugrel
is most beneficial when used in STEMI
and diabetic patients.
Ticagrelor (Brilinta) is the most recently
approved P2Y12 receptor antagonist. It
must be administered with a low ASA
maintenance dose (less than 100mg
daily). Some contraindications include
hypersensitivity to ticagrelor, active
bleeding, and history of intracranial
hemorrhage. Caution should be taken
in patients when taking ticagrelor with
CYP3A4 inducers or inhibitors. The
major side effects of this drug include
bleeding and dyspnea.
Fibrinolytic Agents
Fibrinolytics work by degrading existing
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fibrin clots to open up the blockage in the
arteries in order to increase blood flow.1
In NSTEMI/UA patients, fibrinolytic
therapy is not recommended as clinical
trials showed no significant benefit
and an increased risk of MI and death.3
Fibrinolytic therapy is recommended
in STEMI patients who do not have
timely access to a cardiac catheterization
laboratory.2 Available fibrinolytics
differ based on their fibrin-specificity;
streptokinase is non-specific, whereas
tenectaplase, reteplase and alteplase have
a higher fibrin-specificity.1
Streptokinase non-selectively binds
to either free-flowing or fibrin-bound
plasminogen and converts it to plasmin.5
Plasmin is a proteolytic enzyme that
dissolves the fibrin in the blood clot.
Dose adjustment is not required for
renal or hepatic impairment.2 Absolute
contraindications to fibrinolysis include
history of hemorrhagic stroke, ischemic
stroke within 3 months, known malignant
intracranial neoplasm or arteriovenous
malformation, active internal bleeding,
suspected aortic dissection, or significant
facial or closed head trauma in the last
3 months. Relative contraindications
to fibrinolysis include history of prior
ischemic stroke more than 3 months
ago, significant hypertension with blood
pressure over 180/110 mmHg, recent
trauma, major surgery within 3 weeks,
internal bleeding within 2 to 4 weeks,
oral anticoagulant therapy, active peptic
ulcer or pregnancy. The major side
effect is bleeding. When the patient is on
streptokinase, the monitoring parameters
include performing a complete blood
count (CBC), aPTT, and watching
for signs and symptoms of bleeding.
Streptokinase has a higher risk of
systemic bleeding than the fibrin-specific
fibrinolytics.
Tenecteplase, reteplase, and alteplase
all selectively bind to plasminogens that
are bound to fibrin and convert them
to plasmin.5 Dose adjustment is not
required for renal or hepatic impairment.
The major side effect for these drugs
as with all fibrinolytics is bleeding.2
Contraindications and monitoring
parameters are the same as non-fibrinspecific fibrinolytics. These fibrin-specific
fibrinolytics have higher risk of ICH than
streptokinase.
STEMI Treatment
STEMI patients are at the highest risk

of death according to the Global Registry
of Acute Coronary Events (GRACE)
report, so initial therapy should be
started immediately for these patients,
regardless of cardiac biomarkers levels.1
All STEMI patients should be evaluated
for reperfusion therapy immediately upon
arrival at the emergency department.
Fibrinolytic therapy or primary
percutaneous coronary intervention
(PCI) is considered first line treatment
for restoring coronary artery blood flow
in STEMI patients. Primary PCI is
generally deemed superior to fibrinolytics
due to lower stroke and bleeding risk,
lower mortality rate, and higher success
rate in opening up an occluded coronary
artery than the latter. Timing of treatment
is also crucial to patient survival and
reducing the extent of damages to the
infarcted myocardium. For STEMI
patients presenting to a hospital with a
cardiac catheterization laboratory, PCI
should be performed within 90 minutes of
initial presentation.2 If the hospital is not
equipped to perform primary PCI, the next
treatment choice should be selected based
on individual patient risks such as the time
from onset of symptoms, risk of STEMI
complications, risk of bleeding with
fibrinolysis, presence of shock or severe
heart failure, and the time required for
transfer to a PCI-capable hospital. Ideally,
all patients should be transferred to a
PCI-capable hospital immediately if the
procedure can be performed within 120
minutes of first medical contact. If the
anticipated time for inter-hospital transfer
exceeds the target goal, fibrinolytic
therapy should be chosen as the primary
reperfusion therapy in the absence
of contraindications. If appropriate,
fibrinolytic agents should be administered
within 30 minutes of hospital arrival.
Primary PCI
PCI is a minimally invasive
revascularization procedure that is
performed by skilled interventional
cardiologists in hospitals equipped with
a cardiac catheterization laboratory.6
The procedure can be for diagnostic or
interventional purposes, depending on
whether revascularization is performed.
The initial procedure involves cardiac
catheterization whereby access to coronary
arteries is commonly obtained through
the femoral or radial artery up the aorta
to the suspected occlusion site. After
inserting the diagnostic catheter, coronary

angiography is performed by injecting
contrast dye into the blood to visualize the
coronary arteries and determine narrowing
and blockages of vessels. If, upon
examination, an occlusion site is identified
and revascularization is indicated, balloon
angioplasty can be performed with the
help of a guidewire. Balloon angioplasty
works by dilating the occluded artery with
an inflatable balloon, thereby compressing
the atherosclerotic plaque into the
vessel wall in order to restore coronary
perfusion. Most often, a coronary stent is
deployed and left in place to prevent acute
closure of the artery. Common types of
stents include bare metal stents (BMS)
or drug-eluting stents (DES), which are
coated with an antiproliferative agent
such as sirolimus or paclitaxel. The most
common complication of angioplasty
is restenosis (i.e. a renarrowing of a
previously dilated coronary stenosis). It
occurs most frequently in patients with
angioplasty without stent placement,
less frequently with BMS, and least
frequently with DES. DES implantation
decreases restenosis rates and the need for
subsequent target vessel revascularization
owning to the anti-proliferative effect
of the coated drugs that helps to retard
and minimize cell growth. Despite the
advantage of DES over BMS, it is also
associated with a higher risk of stent
thrombosis, so patients must be adherent
to dual antiplatelet therapy for one year
following the procedure. If patients are
unable to commit to the dual antiplatelet
regimen due to factors such as a high
risk of bleeding, patient incompliance,
or anticipated invasive or surgical
procedures in the next year, BMS should
be considered as an alternative.2 Because
PCI is an invasive procedure, all patients
should receive antithrombotic therapy to
prevent thrombotic complications. The
regimen should include antiplatelet agents
such as ASA, a P2Y12 receptor antagonist,
and a GP IIb/IIIa inhibitor. In addition,
adequate anticoagulation should be
achieved throughout the duration of the
procedure to prevent thrombosis of the
catheter, guidewire, and other thrombotic
complications.
ASA should be administered early to
all patients without contraindications,
most often included in the MONA therapy
upon emergency room arrival and within
24 hours of hospital admission, and
continued indefinitely after the procedure.2
High-dose ASA is preferred for patients
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undergoing primary PCI in order to
achieve a rapid antiplatelet inhibition.
If a stent is implanted, patients should
continue high-dose ASA for a definite
period of time based on the type of stent
selected and switch to low-dose ASA
thereafter. Low-dose ASA is generally
recommended for maintenance due to the
lack of clinical efficacy and risk of major
bleeding, particularly gastrointestinal
bleeding, that is associated with high dose
ASA.
Since ASA only inhibits platelet
aggregation through one pathway, it does
not provide sufficient antiplatelet effect
when used alone. Therefore, concomitant
administration of a P2Y12 receptor
antagonist, such as clopidogrel, prasugrel,
or ticagrelor, is recommended.2 In order
to achieve faster platelet inhibition effects,
a loading dose should be provided to
STEMI patients as early as possible or at
the time of primary PCI. Following PCI,
P2Y12 receptor inhibitor therapy should
be continued on a maintenance dose for at
least 14 days for patients without a stent
and up to 1 year for patients with either
a BMS or DES implanted in the absence
of bleeding complications. In general,
selection of a P2Y12 receptor antagonist
should be based on patient’s bleeding risk,
genetic predisposition, comorbidities, and
additional contraindications for individual
agent. Among the P2Y12 inhibitors,
clopidogrel has the longest history of use
for treatment of ACS. Nonetheless, due
to the pharmacokinetics of clopidogrel,
patients who carry a certain allele of
the CYP450 enzyme may have reduced
capabilities to metabolize the drug,
leading to significant lower levels of
active metabolites and diminished platelet
inhibition. Consequently, clopidogrel may
be undesirable for these patients. Newer
agents such as prasugrel and ticagrelor
had demonstrated greater efficacy in
platelet inhibition and improved patient
outcome comparing to clopidogrel in
their corresponding landmark trials,
namely TRITON-TIMI 38 and PLATO
respectively.7,8
GP IIb/IIIa inhibitors work on the final
common pathway of platelet aggregation
and provide additional platelet inhibition
when used in combination with other
antiplatelet agents. The adjunctive use of
GP IIb/IIIa inhibitors in STEMI patients
at the time of PCI should be considered
on an individual basis and should depend
on factors such as choice of anticoagulant,
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presence of large thrombus, or inadequate
P2Y12 receptor inhibitor loading.2 While
GP IIb/IIIa inhibitors may be used
together with either UFH or enoxaparin,
co-administration with bivalirudin should
be avoided if possible due to increased
risk of major bleeding. If abciximab or
tirofiban is chosen, a bolus dose should
be administered prior to continuous IV
infusion. For eptifibatide, two boluses
should be given 10 minutes apart prior
to continuous IV infusion. Dosing
adjustment is required for eptifibatide
and tirofiban in patients with renal
dysfunction. For patients presenting
with severe renal or hepatic impairment,
abciximab may be a better alternative
since no dose adjustment is necessary.
Following PCI, abciximab can be
continued for up to 12 hours, eptifibatide
for 12 to 18 hours, and tirofiban for
up to 18 hours at the discretion of the
physician.9
Anticoagulants that are recommended
for STEMI patients undergoing primary
PCI include UFH and bivalirudin.2
UFH has a long standing history
of use in STEMI and is the most
common anticoagulant used in cardiac
catheterization laboratory.1 One advantage
of UFH over other anticoagulants is the
availability of an antidote (i.e. protamine),
which is very useful if a reversal of
anticoagulation is necessary. Intensity
of anticoagulation, which can be easily
monitored at the bedside with ACT, is
often dependent on whether a GP IIb/
IIIa inhibitor has been administered.
Additional boluses may be given as
needed to maintain therapeutic ACT
levels. Due to bleeding concerns,
frequent monitoring is required and is
often deemed a limitation for its use. For
patients with a contraindication for UFH
or are at high risk of bleeding, bivalirudin
may be a reasonable alternative to UFH.
Bivalirudin has been shown to have a
lower bleeding risk than combination of
UFH and a GP IIb/IIIa inhibitor, making
it the preferred agent for STEMI patients
at high risk of bleeding.2 However,
bivalirudin has also been associated with
increased risk of acute stent thrombosis.10
Since the majority of patients receiving
PCI have stent placement, bivalirudin
should be reserved for those with HIT,
higher risk of bleeding, or when the use
of GP IIb/IIIa inhibitors is undesirable.2
Other anticoagulants such as enoxaparin
and fondaparinux may be used in primary

PCI in certain ACS settings although
they are not specifically recommended
as first line anticoagulants in primary
PCI. Enoxaparin may be continued
uninterrupted during rescue PCI in patients
who received enoxaparin with prior
fibrinolytic therapy.2 A supplemental IV
dose of enoxaparin should be administered
if the last dose was administered
between 8 and 12 hours earlier. After
12 hours, patients should either receive
a full dose of enoxaparin or switch to
UFH or bivalirudin for anticoagulation.
Fondaparinux should not be used alone
because it does not provide adequate
anticoagulation for PCI and is associated
with higher risk of catheter thrombosis.2
Therefore, a second anticoagulant like
UFH or bivalirudin should be administered
together if fondaparinux is to be selected
for specific reasons. Regardless of choice
of anticoagulant, anticoagulant therapy
should be discontinued immediately after
PCI to avoid bleeding complications.
Fibrinolysis
Fibrinolytic therapy is recommended for
STEMI patients who are ineligible for PCI
and present to hospital within 12 hours
of the onset of chest discomfort.2 This
time frame has been shown to be most
beneficial in decreasing the incidence of
mortality. For STEMI patients presenting
to the hospital within 12 to 24 hours
of symptom onset, fibrinolytic agent
may be administered if they experience
ongoing ischemia. Because fibrinolytic
agents work by dissolving existing clots,
patients at high risk of bleeding should
be assessed for absolute and relative
contraindications (as described previously)
prior to administration.1 While
patients presenting with any absolute
contraindication are precluded from
receiving fibrinolytic therapy, patients
presenting with a relative contraindication
may still receive treatment if the risk
of death from MI outweighs the risk of
major bleeding. Special consideration
should be taken in patients over 75 years
of age. Although the use of fibrinolytics
in this age group is not recognized as a
contraindication, this patient population
has a higher MI mortality rate associated
with fibrinolytic use compared to a
younger patient population. Therefore,
careful dosing efforts should be made
to prevent bleeding when administering
fibrinolytic and anticoagulation therapies
to these patients. In terms of selection of
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a fibrinolytic agent, fibrin-specific agents
such as tenecteplase, reteplase, or alteplase
are preferred over non-fibrin-specific agent
like streptokinase. All fibrinolytic agents
may potentially cause major bleeding
including intracranial hemorrhage (ICH).
Regardless of the choice of a fibrinolytic
agent, adjunctive antithrombotic therapy,
such as anticoagulant and/or antiplatelet
therapies, should be initiated for STEMI
patients receiving fibrinolytic therapy.2
Antiplatelet therapy with fibrinolysis
includes both ASA and clopidogrel,
which should be administered before or
with the fibrinolytic agent. ASA should
be continued indefinitely following
fibrinolytic therapy. Clopidogrel should
be continued for at least 14 days and up
to 1 year based on individual patient’s
risk of reinfarction. Currently, prasugrel
and ticagrelor are not recommended to be
administered with fibrinolytics because
these agents have not been studied with
fibrinolytic therapy. GP IIb/IIIa inhibitors
are also not recommended for use with
fibrinolytics. Furthermore, patients should
receive an anticoagulant in addition to
their fibrinolytic regimen in order to
minimize vessel obstruction and prevent
re-occlusion. Enoxaparin is the preferred
agent for anticoagulation with fibrinolytic
therapy. However, other anticoagulants
such as UFH and fondaparinux are
also good alternatives. The selected
anticoagulant should be continued for a
minimum of 48 hours, up to 8 days or
until revascularization is performed.
In the event of re-occlusion or failed
reperfusion after fibrinolytic therapy,
patients may show ongoing ischemic
symptoms, or worst, develop cardiogenic
shock or acute severe heart failure.2 These
patients are at high risk of mortality, and
are good candidates for a rescue PCI and
should be transferred to a PCI-capable
hospital immediately. If these patients
have not received a previous loading dose
of clopidogrel with fibrinolytic therapy,
a supplemental loading dose should be
given before or at the time of PCI.
Coronary Artery Bypass Graft Surgery
(CABG)
CABG is a surgical alternative to PCI or
medical management for severe coronary
artery disease.2 The indications for
CABG are based on severity of ischemia,
coronary anatomy, and left ventricular
function. In the setting of STEMI, major
indications for CABG include patients

with multi-vessel (> 3) disease, significant
left anterior descending artery stenosis,
cardiogenic shock, or failed primary
PCI.11 A number of clinical trials have
found CABG to be superior to aggressive
medical management or PCI in the long
term survival of high risk patients.12,13 The
surgery is performed by cardiothoracic
surgeons rather than cardiologists. During
the surgical procedure, an artery (internal
mammary or radial) or vein (usually the
saphenous) harvested from another part
of the body is used to form a connection
between the aorta and the section of the
coronary artery distal to the occlusion site,
and consequently, bypassing the occluded
area and restoring coronary blood flow.14
Although this type of surgery most often
requires a cardiopulmonary bypass
machine, it may be performed “off-pump”
by skilled cardiac surgeons and can
significantly reduce serious bleeding and
thrombotic complications (stroke, MI)
after the procedure.11
Since CABG is an invasive procedure
and puts the patients at high risk of
bleeding, all antiplatelet agents, except
for ASA, should be withheld before the
procedure.11 Preoperative ASA use has
been shown to reduce operative morbidity
and mortality rates in CABG patients. In
contrast, use of P2Y12 receptor antagonists
is associated with increased rates of
major bleeding which necessitates blood
transfusions in post-CABG patients.
Therefore, patients undergoing urgent
CABG should discontinue clopidogrel
and ticagrelor for at least 24 hours prior
to surgery. Often, CABG may be an
elective surgery for certain patients with
high risk of severe MI. In these patients
referred for elective CABG, clopidogrel
and ticagrelor should be discontinued
for at least 5 days and prasugrel for at
least 7 days to decrease major bleeding
complications. Other IV antiplatelet
agents such as eptifibatide and tirofiban
should be withheld for at least 2 to 4
hours and abciximab for at least 12 hours
before surgery to limit blood loss and
transfusions. During the surgery, adequate
anticoagulation should be maintained
with UFH per institutional practice.3 In
the absence of contraindications, betablockers should be given 24 hours before
CABG to decrease the incidence of
postoperative atrial fibrillation. Because
the CABG procedure puts the patient
at increased risk of developing wound
or systemic infections, prophylactic

antibiotics (a first or second generation
cephalosporin with or without MRSA
coverage) should be given to all patients.
In addition, tight postoperative glycemic
control and lipid management are
necessary to ensure the best possible
outcome for all patients.
NSTEMI/UA Treatment
Invasive vs. Conservative Strategy
Initial treatment of NSTEMI/UA
involves the use of the Thrombolysis In
Myocardial Infarction (TIMI) scoring
system.1 This system calculates the risk of
composite endpoint of death, MI, or urgent
need for revascularization within 14 days.
One point (1) is assigned if the patient has
each of the following: age greater than 65,
three or more cardiac risk factors (HTN,
DM, hyperlipidemia, smoking, family
history), known history of CAD (greater
than 50% stenosis seen on angiogram),
two or more episodes of chest discomfort
in the last 24 hours, ASA use within the
last 7 days, elevated cardiac biomarkers,
and ST-segment deviation on an ECG.
These criteria are serious risk factors for
developing either an MI, death, or urgent
revascularization within the next 14 days.
Patients presenting with multiple criteria
should be treated urgently with an invasive
strategy. ASA should be initially given to
NSTEMI/UA patients, with a loading dose
of clopidogrel, prasugrel, or ticagrelor
being as a substitute if ASA is intolerant to
the patient.4
Initial Invasive Strategy
An initial invasive strategy involves
cardiac catheterization, usually within 4
to 24 hours following hospital admission,
followed by either revascularization
with PCI or CABG.3 This strategy is
recommended for patients with a moderate
to high risk of an event according to their
TIMI score and other high risk features
such as patients who have refractory
angina, hemodynamic or electrical
instability, or initially stabilized NSTEMI/
UA with an elevated risk for clinical
events.4 Patients with definite NSTEMI/
UA who are at moderate to high risk
should be given dual antiplatelet therapy
upon presentation, with ASA being
one of the agents.3 The choice for the
second antiplatelet agent can be either
clopidogrel, prasugrel, ticagrelor, and a GP
IIb/IIIa inhibitor (tirofiban and eptifibatide
being the preferred agents).4 These agents
are to be given either before PCI or at
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the time of PCI. This is to reduce the
risk of ischemic events that may occur
during PCI, as trauma frequently occurs
during these types of procedures. This
results in platelet activation, aggregation,
and subsequently a coronary thrombosis.
Anticoagulants are needed in invasive
strategies because they limit thrombotic
complications of ischemic events,
especially during angioplasty. They also
help prevent thrombosis of catheters and
guidewires used during these procedures.
Depending on the results of the diagnostic
angiography, there are three possible postangiography management strategies one
can initiate, depending on the findings of
the angiography: CABG, PCI, or medical
therapy.3
CABG
CABG surgery is strongly
recommended in NSTEMI/UA patients
with significant left main coronary artery
disease (CAD), 3-vessel disease, 2-vessel
disease, or when PCI is not optimal or
possible.11 If CABG is selected, continue
ASA therapy; discontinue clopidogrel
for least 5 days, prasugrel for at least 7
days, and ticagrelor for at least 5 days
prior to CABG procedure.4 ASA is used
to provide antiplatelet therapy during the
procedure, while the other antiplatelets
are discontinued as they incur a serious
risk of bleeding.3 Prasugrel has an earlier
discontinuation time than clopidogrel
and ticagrelor because it has a much
higher risk of bleeding than those two
agents. Intravenous GP IIb/IIIa inhibitors
(eptifibatide and tirofiban) must also be
discontinued 2 – 4 hours prior to CABG
procedure. UFH is to be continued, while
enoxaparin must be discontinued 12 to
14 hours, fondaparinux 24 hours, and
bivalirudin 3 hours prior to CABG.
PCI
PCI is recommended for NSTEMI/UA
patients with 1- or 2- vessel CAD and
multi-vessel coronary disease with suitable
coronary anatomy.3 If PCI is selected,
ASA is to be continued. A loading dose
of clopidogrel, prasugrel, or ticagrelor,
and/or GP IIb/IIIa should be given if
not given prior to angiography.4 GP IIb/
IIIa inhibitors are highly recommended
in addition to ASA and P2Y12 inhibitors
in PCI patients to reduce morbidity and
mortality based on several randomized
control trials. A study involving
abxicimab or placebo given to patients
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showed that the patient group receiving
abxicimab in addition to clopidogrel
showed a significant reduction in the
primary end points of death, nonfatal
reinfarction, or urgent target-vessel
vascularization within 30 days.15 Once
PCI is completed, anticoagulant therapy
can be discontinued.3
Medical Therapy
Medical therapy is recommended for
post-angiographic NSTEMI/UA patients
with no signs of significant obstructive
CAD on angiography.4 Antiplatelet and
anticoagulant therapy is used in these
patients at a physician’s discretion. If
CAD is detected on angiography, ASA
should be continued.3 A loading dose of
clopidogrel or ticagrelor should be given
to provide a rapid antiplatelet effect if not
given prior to angiogram, as maintenance
doses require a few days to achieve full
effect. Prasugrel is not recommended
because it has only proven benefit in
patients undergoing PCI. IV GP IIb/
IIIa inhibitors should be discontinued
after at least 12 hours if it was started
before the angiogram. IV UFH should
be continued for at least 48 hours or
enoxaparin or fondaparinux for the
duration of hospitalization, up to 8 days.
Bivalirudin can be continued at a dose
of 0.25 mg/kg/hr for up to 72 hours at a
physician’s discretion if it was given prior
to diagnostic angiography.
Initial Conservative Strategy
An initial conservative treatment
strategy is recommended for NSTEMI/
UA patients with a low stratified TIMI risk
score.4 This treatment strategy involves
initial medical management, followed by
catheterization and revascularization if
an ischemic event occurs despite active
drug treatment. Patients presenting with
a low risk of death, MI (either initial or
recurrent), or refractory angina are usually
evaluated in the emergency department.
Serum biomarkers are obtained from the
patient, and if they are negative for these
biomarkers, the patient may be directed
to a general medical area to undergo ECG
monitoring for any ischemic events or
arrhythmias. In addition, a stress test,
such as an exercise stress test, can be
performed. If there are positive findings
in the stress test, diagnostic angiography
should be performed.
For these low risk patients, ASA should
be initially given, along with either

clopidogrel or ticagrelor (loading dose
followed by daily maintenance doses)
as soon as possible after admission.4
ASA is to be continued indefinitely
while clopidogrel or ticagrelor should
be continued for one month and up to 12
months. If the patient is stable and their
symptoms are controlled, they can be
discharged with recommended antiplatelet
therapy such as clopidogrel or ticagrelor
for a duration ranging from one month to
one year.
If an ischemic event does occur
while the patient is on drug therapy,
an angiography should be performed,
and invasive strategies (CABG, PCI, or
medical therapy for CAD) are initiated.4
Prior to angiography, either an IV GP IIa/
IIIb inhibitor (tirofiban or eptifibatide)
or a P2Y12 inhibitor (clopidogrel or
ticagrelor, loading dose followed by daily
maintenance doses) should be added to
ASA and anticoagulant therapy.
Discharge Medications and Secondary
Prevention
Once a patient has received appropriate
treatment for ACS and is recovering, it is
imperative that they be put on appropriate
medications for secondary prevention of
ischemic events prior to discharge.1 ACS
patients should be on ASA indefinitely,
in addition to a beta-blocker and statin
therapy. ASA has been shown in a large
number of clinical trials to decrease the
risk of death, recurrent MI, and stroke
following an MI.3 If the patient is unable
to take ASA due to contraindications,
clopidogrel is recommended. All patients
should be given sublingual nitroglycerin
(SL NTG) tablets or a lingual nitroglycerin
spray in the event if they experience
recurrent chest pain and discomfort. Betablockers are recommended indefinitely
because they have been shown to decrease
the incidence of recurrent MI. However,
they are contraindicated in HF patients
with acute decompensation. ACE
inhibitors are indicated in patients who
are not at blood pressure goals on betablocker therapy, as well as patients with
a reduced ejection fraction or diabetic
patients. Angiotensin II receptor blockers
can be given if the patient suffers from
ACE inhibitor induced angioedema.
According to ACC/AHA guidelines, the
goal blood pressure for HTN patients with
ACS is 130/80 mmHg. In addition, it is
imperative that ACS patients receive lipidlowering agents such as statins, as they are
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used to prevent total mortality and stroke.
Furthermore, all ACS patients should be
provided appropriate pharmacological and
non-pharmacological therapy to achieve a
goal LDL level of less than 100 mg/dL.
Other modifiable risk factors such as
diabetes mellitus and smoking are also
important in secondary prevention of
ACS. According to ADA guidelines, the
goal HgB A1c level for ACS patients with
diabetes is < 7%. Smoking cessation is
correlated with a significant reduction in
all-cause mortality in all ACS patients, and
can be achieved by various products such
as varenicline or nicotine patches/gums.
Proper diet and exercise is also important,
as maintaining an ideal weight is essential
in preventing the reoccurrence of ACS
events.
In certain patients with atrial fibrillation
with a CHADS2 score of greater
than or equal to 2, mechanical heart
valves, venous thromboembolism, or a
hypercoagulable disorder, warfarin may be
indicated.2 Co-administration of warfarin
and dual antiplatelet therapy may put
patients at high risk of severe bleeding.
Therefore, the duration of use should be
limited to the extent of anticoagulation
deemed necessary. A lower INR goal (2.0
– 2.5) should also be considered.
Conclusions
Acute coronary syndromes contribute
to a significant number of cardiovascular
related deaths in the US.1 Pharmacists
have an important role in managing
the disease state for the patient from
the beginning in the emergency room
to discharging the patients from the
hospital. Pharmacists need to be vigilant
in selecting the most appropriate therapy
for their patients based on the type of
ACS and patient specific factors in order
to help reduce the risk of developing side
effects and complications, re-infarction,
and most importantly, death. Pharmacists
are an integral part of the health care team
that can provide dosing and monitoring
recommendations for medications, as well
as provide education to patients to prevent
recurrent cardiac events.
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Table for Continuing Education
Article - Acute Coronary
Syndromes: Current Treatment
Guidelines and Updates
Fibrinolytics

Alteplase (tPA)
{Activase®}

Procedure[ACC/AHA
Guideline
Recommendations]
Fibrinolytic therapy ≤
30 min of hospital
arrival [IB]

Reteplase (rPA)
{Retavase®}

Fibrinolytic therapy ≤
30 min of hospital
arrival [IB]

Tenecteplase
(TNK-tPA)
{Tnkase®}

Fibrinolytic therapy ≤
30 min of hospital
arrival [IB]

Streptokinase
{Streptase®}

Fibrinolytic therapy ≤
30 min of hospital
arrival [IB]

Unfractionated
Heparin (UFH)

Fibrinolytic therapy
[IC]

Dose
Adjustment

Warnings / DDI/
Contraindications*

Monitoring

Dose and Duration of Therapy

No

 Prior ICH*
 Known structural
cerebrovascular
lesions, such as
arterial venous
malformation*
 Known intracranial
malignant
neoplasm*
 Ischemic stroke ≤ 3
months*
 Active bleeding*
(excluding menses)
 Significant closed
head or facial
trauma ≤ 3
months*
 Active bleeding*
 History of HIT*
 Risk of severe
bleeding
 Recent stroke

 CBC
 aPTT
 Bleeding

 15 mg IV bolus, followed by 0.75 mg/kg
IV (max 50 mg) over 30 min, then 0.5
mg/kg (max 35 mg) over 60 min (max
dose = 100 mg)
 10 unit IV x 2, 30 min apart

No

PCI [IC]

Enoxaparin
(LMWH)
{Lovenox®}

Anticoagulants

Source: Adapted from
information found in references
1,2,11,16.
DDI indicates drug-drug
interaction; ICH, intracranial
hemorrhage; CBC, complete
blood count; aPTT, activated
partial thromboplastin time; HIT,
heparin-induced thrombocytopenia;
ACT, activated clotting time; GPI,
glycoprotein IIb/IIIa inhibitor; IV,
intravenous; PCI, percutaneous
coronary intervention; LMWH,
low molecular weight heparin; SCr,
serum creatinine; CrCl, creatinine
clearance; SC, subcutaneous;
CABG, coronary artery bypass
graft; BBW, black box warning;
PO, per os (by mouth); BMS, bare
metal stent; DES, drug eluting
stent.

Drug

Fondaparinux
{Arixtra®}

Bivalirudin
{Angiomax®}
Drug

Full article, including charts, is
available for download on the AzPA
website in the Journal archives.

Aspirin
(ASA)

Abciximab
{Reopro®}

Eptifibatide
{Integrilin®}

Antiplatelets

Tirofiban
{Aggrastat®}

Clopidogrel
{Plavix®}

Prasugrel
{Effient®}

Ticagrelor
{Brilinta®}
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Fibrinolytic therapy
[IA]

Reduce if
CrCl < 30
mL/min

 < 60 kg: 30 mg IV bolus
60 – 69 kg: 35 mg IV bolus
70 – 79 kg: 40 mg IV bolus
80 – 89 kg: 45 mg IV bolus
> 90 kg: 50 mg IV bolus
 1.5 MU (million units) IV over 60 min

 aPTT: 50 – 70
sec
 ACT: 200-300
sec (with GPI);
250-350 sec
(no GPI)
 HIT
 Bleeding
 SCr
 HIT
 Bleeding

 60 units/kg IV bolus, then 12 units/kg/hr
IV infusion
 Continue for 48 hours
 With GPI: 50-70 units/kg IV bolus
No GPI: 70-100 units/kg IV bolus
 Discontinue at the end of PCI

 Active bleeding*
 < 75 y.o.: 30 mg IV bolus, then 1mg/kg
 History of HIT
SC every 12 hr
 Risk of severe
> 75 y.o.: 0.75 mg/kg SC every 12 hr
bleeding
 Continue for the duration of
 Recent stroke
hospitalization (up to 8 days)
 Avoid if CrCl < 15
PCI after fibrinolytic
 1 mg/kg SC every 12 hours (if last dose >
mL/min
therapy [IB]
8 hours prior to PCI, administer 0.3
 Avoid if CABG
mg/kg IV bolus)
surgery
 Discontinue at the end of PCI
Fibrinolytic therapy
No
 Active bleeding*
 SCr
 2.5 mg IV, then 2.5 mg SC daily
[IB]
 Risk of severe
 Bleeding
 Continue for the duration of
bleeding
hospitalization (up to 8 days)
 Avoid if CrCl < 30
PCI [III, B]
 2.5 mg IV, then 2.5 mg SC daily (MUST
mL/min
*not as
administer UFH 50-60 units/kg IV bolus
 Increase risk of
monotherapy*
prior)
catheter
 Discontinue at the end of PCI
thrombosis if used
as monotherapy
 0.75 mg /kg IV bolus, then 1.75
PCI [IB]
Severe renal myocardial
Active bleeding* infarction
 SCr
ST-elevation
(STEMI)
*can be used in place
function
 Risk of severe
 Bleeding
mg/kg/hr IV
of
UFH
+
GPI
if
high
bleeding
Dose
Discontinue
at theofend
of PCI
Procedure[ACC/AHA
Dose
Warnings / DDI/
Monitoring
and Duration
Therapy
risk
of bleeding
Contraindications*
Increase risk of
Guideline
Adjustment
[IIa,
B]*
stent thrombosis
Recommendations]
Initial treatment after
No
 Hypersensitivity
 162-325 mg before PCI, then 81 mg
 Bleeding
hospital admission
 Active bleeding
maintenance dose daily indefinitely
[IB]
 Risk of severe
 If a stent is placed after PCI, continue
bleeding
162-325 mg daily
- for a minimum of 30 days (bare metal
stent)
- for 3 months (sirolimus-eluting stent)
- for 6 months (paclitaxel-eluting stent)
- then continue 75-162 mg daily
indefinitely
PCI [IIa, A]
No
 Active bleeding*
 SCr
 0.25 mg/kg IV bolus, then 0.125
 Thombocytopenia*  Platelet count
mcg/kg/min IV infusion
 Prior stroke ≤ 2
 Bleeding
 Continue for up to 12 hr
years*
PCI [IIa, B]
CrCl <50
 Active bleeding*
 SCr
 180 mcg/kg IV bolus x 2, then 2
mL/min:
 Prior stroke ≤ 30
 Platelet count
mcg/kg/min IV infusion
reduce
days*
 Bleeding
 Continue for 12 – 18 hr after PCI
infusion 50%  Renal dialysis*
 Thombocytopenia
 25 mcg/kg IV bolus, then 0.15
PCI [IIa, B]
CrCl <30
 Active bleeding*
 SCr
mL/min:
 Thombocytopenia*  Platelet count
mcg/kg/min IV infusion
reduce
 Prior hemorrhagic
 Bleeding
 Continue for 18 hr after PCI
infusion 50%
stroke*
Fibrinolytic [IA]
No
 Hypersensitivity
 SCr
 < 75 y.o.: 300 mg PO loading dose, then
 Active bleeding*
 Bleeding
75 mg
 Risk of severe
daily maintenance dose
bleeding
> 75 y.o.: 75 mg daily
 Reduced 2C19
 Continue for 14 days to 1 year in
absence of bleeding
function (BBW)
 Caution with 2C19
PCI [IB]
 300 mg (PCI ≤ 24 hr) or 600 mg (PCI > 24
inhibitors
hr) PO loading dose, then 75 mg PO
 Hold 5 days prior
daily maintenance dose
to CABG surgery
 Continue for 14 days if no stent is
placed or 1 year if either a BMS or DES
is placed
PCI [IB]
No
 Active bleeding*
 SCr
 60 mg PO loading dose, then 10 mg PO
 History of TIA or
 Bleeding
daily maintenance dose
stroke (BBW)
 Continue for 14 days if no stent is
 Age > 75 y.o.(BBW)
placed or 1 year if either a BMS or DES
 Weight < 60 kg
is placed
(BBW)
 Hold 7 days prior
to CABG surgery
PCI [IB]
No
 Hypersensitivity
 SCr
 180 mg PO loading dose, then 90 mg PO
 Active bleeding*
 Bleeding
twice a day maintenance dose
 History of ICH
 Continue for 14 days if no stent is
placed or 1 year if either a BMS or DES
(BBW)
is placed
 Must use with low
dose aspirin (BBW)
 Caution with 3A4
inducers/ inhibitors
 Hold 5 days prior
to CABG surgery

Non-ST elevation myocardial infarction (NSTEMI) / Unstable angina (UA)
Drug

Procedure[ACC/AHA
Guideline
Recommendations]

Dose
Adjustment

Warnings / DDI/
Contraindications*

Unfractionated
Heparin (UFH)

Invasive strategy:
 Before PCI [IA]
 PCI [IA]

No






Active bleeding*
History of HIT*
Risk of severe bleeding
Recent stroke

Conservative strategy
[IA]

Enoxaparin (LMWH)
{Lovenox®}

Invasive strategy:
 Before PCI [IA]
 PCI [IA]

Reduce if
CrCl < 30
mL/min

Anticoagulants

Conservative strategy
[IA]

Fondaparinux
{Arixtra®}

Bivalirudin
{Angiomax®}








Invasive strategy:
 Before PCI [IB]
 PCI [III,C]
*not as
monotherapy*
Conservative strategy
[IB]

No

Invasive strategy:
 Before PCI [IB]
 PCI [IB]
*can be used if high
risk of bleeding*

Severe renal
function













Active bleeding*
History of HIT
Risk of severe bleeding
Recent stroke
Avoid if CrCl < 15
mL/min
Avoid if CABG surgery
(discontinue 12-24 hrs
prior)
Active bleeding*
Risk of severe bleeding
Avoid if CrCl < 30
mL/min
Avoid if CABG surgery
(discontinue 24 hrs
prior)
Increase risk of catheter
thrombosis if used as
monotherapy
Active bleeding*
Risk of severe bleeding
Avoid if CABG surgery
(discontinue 3 hrs prior)
Increase risk of stent
thrombosis

Conservative strategy:
 Angiography [IB]

Non-ST elevation myocardial infarction (NSTEMI)

Monitoring

Dose and Duration of Therapy

 aPTT: 50 –
70 sec
 ACT: 200300 sec
(with GPI);
250-350
sec (no
GPI)
 HIT
 Bleeding
 SCr
 HIT
 Bleeding

 60 units/kg IV bolus, then 12
units/kg/hr IV infusion
 Continue for 48 hr or discontinue
at the end of PCI

 SCr
 Bleeding

 SCr
 Bleeding

 Before PCI, 0.1 mg/kg IV bolus,
then 0.25 mg/kg/hr IV infusion
 If given before PCI, 0.5 mg/kg IV
bolus, then 1.75 mg/kg/hr IV
infusion
 If not given before PCI, 0.75
mg/kg IV bolus, then 1.75
mg/kg/hr IV infusion
 Discontinue at the end of PCI
 Before angiography, 0.1 mg/kg IV
bolus, then 0.25 mg/kg/hr IV
infusion

Discontinue
at the end of
/ Unstable angina
(UA)
angiography or continue at 0.25
Monitoring
Dose and Duration of Therapy
mg/kg/hr for up to 72 hr if
prolonged anticoagulation
necessary

Dose
Adjustment

Warnings / DDI/
Contraindications*

Aspirin (ASA)

Initial treatment after
hospital admission
[IA]

No

 Hypersensitivity
 Active bleeding
 Risk of severe bleeding

 Bleeding

Abciximab
{Reopro®}

Invasive strategy:
 PCI [IA]

No

 Active bleeding*
 Thombocytopenia*
 Prior stroke ≤ 2 years*

Eptifibatide
{Integrilin®}

Invasive strategy:
 Before PCI [1B]
 PCI [IA]

CrCl <50
mL/min:
reduce
infusion 50%






 SCr
 Platelet
count
 Bleeding
 SCr
 Platelet
count
 Bleeding

Antiplatelets

Conservative strategy:
 Before angiography
[IIb, B]
 Angiography [IA]
Invasive strategy:
 Before PCI [1B]
 PCI [IA]
Conservative strategy:
 Before angiography
[IIb, B]
 Angiography [IA]

CrCl <30
mL/min:
reduce
infusion 50%

 Active bleeding*
 Thombocytopenia*
 Prior stroke ≤ 2 years*

Clopidogrel
{Plavix®}

Invasive strategy:
 Before PCI [1B]
 PCI [IA]

No






Conservative strategy:
 Before angiography
[IB]
 Angiography [IB]
Prasugrel
{Effient®}

Invasive strategy:
 PCI [IB]



No







Ticagrelor
{Brilinta®}

Invasive:
 Before PCI [1B]
 PCI [IB]
Conservative strategy:
 No angiography [IB]
 Angiography [IB]

No








Hypersensitivity
Active bleeding*
Risk of severe bleeding
Reduced 2C19 function
(BBW)
Caution with 2C19
inhibitors
Hold 5 days prior to
CABG surgery
Active bleeding*
History of TIA or stroke
(BBW)
Age > 75 y.o.(BBW)
Weight < 60 kg (BBW)
Hold 7 days prior to
CABG surgery
Hypersensitivity
Active bleeding*
History of ICH (BBW)
Must use with low dose
aspirin (BBW)
Caution: 3A4 inducers/
inhibitors
Hold 5 days prior to
CABG surgery

 2.5 mg SC daily (MUST administer
UFH 50-60 units/kg IV bolus
prior)
 Discontinue at the end of PCI
 2.5 mg SC daily
 Continue for the duration of
hospitalization (up to 8 days)

Procedure[ACC/AHA
Guideline
Recommendations]

Tirofiban
{Aggrastat®}

 1 mg/kg SC every 12 hours (if last
dose > 8 hours prior to PCI,
administer 0.3 mg/kg IV bolus)
 Discontinue at the end of PCI
 1 mg/kg SC every 12 hours
 Continue for the duration of
hospitalization (up to 8 days)

Drug

Active bleeding*
Prior stroke ≤ 30 days*
Renal dialysis*
Thombocytopenia

 60 units/kg IV bolus, then 12
units/kg/hr IV infusion
 Continue for 48 hr or until
discharge

 SCr
 Platelet
count
 Bleeding

 SCr
 Bleeding

Table for Continuing Education
Article - Acute Coronary
Syndromes: Current Treatment
Guidelines and Updates
Source: Adapted from
information found in references
1,3,4,11.
DDI indicates drug-drug
interaction; ICH, intracranial
hemorrhage; aPTT, activated
partial thromboplastin time; HIT,
heparin-induced thrombocytopenia;
ACT, activated clotting time; GPI,
glycoprotein IIb/IIIa inhibitor; IV,
intravenous; PCI, percutaneous
coronary intervention; LMWH,
low molecular weight heparin; SCr,
serum creatinine; CrCl, creatinine
clearance; SC, subcutaneous;
CABG, coronary artery bypass
graft; BBW, black box warning;
PO, per os (by mouth).

 162-325 mg before procedure,
then 81 mg maintenance dose
daily indefinitely
 If a stent is placed after PCI,
continue 162-325 mg daily
- for at least 30 days (bare metal
stent)
- for 3 months (sirolimus-eluting
stent)
- for 6 months (paclitaxel-eluting
stent)
- then continue 75-162 mg daily
indefinitely
 0.25 mg/kg IV bolus, then 0.125
mcg/kg/min IV infusion
 Continue for up to 12 hr after PCI
 180 mcg/kg IV bolus x 2 (10 min
apart), then 2 mcg/kg/min IV
infusion
 Continue for 12 – 18 hr after PCI
 180 mcg/kg IV bolus, then 2
mcg/kg/min IV infusion
 If no angiography, discontinue
 If angiography, continue for up to
72 hr
 25 mcg/kg IV bolus, then 0.15
mcg/kg/min IV infusion
 Continue for up to 18 hr after PCI
 50 mcg/mL administered at a
rate of 0.4 mcg/kg/min over 30
min, then 0.1 mcg/kg/min IV
infusion
 If no angiography, discontinue
 If angiography, continue for up to
72 hr
 300 – 600 mg PO loading dose,
then 75 mg PO daily maintenance
dose
 If PCI, continue for at least 12
months.
 If no PCI, continue for up to 12
months

 SCr
 Bleeding

 60 mg PO loading dose, then 10
mg PO daily maintenance dose
 Continue for up to 12 months

 SCr
 Bleeding

 180 mg PO loading dose, then 90
mg PO daily maintenance dose
 If PCI, continue for at least 12
months
 If no PCI, continue for up to 12
months
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Continuing Education Quiz Questions
Acute Coronary Syndromes: Current Treatment Guidelines and Updates ACPE UAN#0100-0000-13-056-H01-P
1. A 72-year old female presents to the
hospital for chest pain that started about 11
hours ago, but has been getting worse in
the last 30 minutes. Her EKG reveals STsegment depression and T- wave inversions.
Her first two set of cardiac biomarkers reveals
elevated CK-MB and troponins. Which of the
following is the most likely diagnosis?
a. NSTEMI
b. STEMI
c. Unstable angina
d. Non-cardiac cause of chest pain
e. Cannot determine based on the information
given
2. A 68-year old female patient presents to
the hospital with crushing chest pain that
started 30 minutes ago. She has received 3
doses of sublingual nitroglycerin, but has
been getting worse in the last 15 minutes.
According to her past medical history, she
has asthma and heart failure (left ventricular
ejection fraction 10-15%). Her vital: BP
156/92, HR 72, O2 saturation on room air
79%. Which of the following is the BEST
recommendation for this patient?
a. Chew aspirin 325 mg, titrate oxygen to
100% O2 saturation, nitroglycerin 0.4 mg SL,
metoprolol 25 mg IV
b. Chew aspirin 325 mg, titrate oxygen to
100% O2 saturation, nitroglycerin 0.4 mg SL,
metoprolol 25 mg PO
c. Chew aspirin 325 mg, morphine 2 mg IV,
and titrate oxygen to 100% O2 saturation
d. Chew aspirin 325 mg. morphine 2 mg
IV, titrate oxygen to 100% O2 saturation,
metoprolol 25 mg IV
e. Chew aspirin 325 mg. morphine 2 mg
IV, titrate oxygen to 100% O2 saturation,
metoprolol 25 mg PO
3. TG is a 60 year old female that was
presented to the emergency room with
complaints of throbbing chest pain. She was
initially given 3 SL tablets of NTG in the last
15 minutes, however she is still having chest
pain. Her O2 sats are at 86%. Her LVEF is
at 30% according to TTE. What medications
and or therapy should this patient being
receiving next?
a. Initial invasive strategy with preference
for PCI
b. IV morphine + ASA
c. IV morphine + oxygen administered via
nasal cannula + ASA
d. Patient does not need anything, as this not
an ACS case

4. BN is an 80 year old male who develops
crushing chest pain that started 30 minutes
ago. The EKG in the ambulance reveals
that the patient is having a STEMI. The
nearest hospital with a cardiac catheterization
laboratory is three hours away. What is the
most appropriate initial treatment strategy for
this patient?
a. Transfer directly to hospital with
catheterization laboratory for PCI
b. Admit to nearest hospital for fibrinolytic
therapy
c. Admit to nearest hospital for diagnostic
stress test
d. Admit to nearest hospital for CABG
5. JT is a 75 year old male who presents to
the emergency department with complaints of
chest pain. He states that he has 3 episodes of
chest pain in the past 24 hours. In addition,
he has a history of coronary artery disease,
as well at hypertension and diabetes. A
preliminary ECG shows sinus tachycardia.
What is his risk assessment based on his TIMI
score?
a. Low risk
b. Moderate risk
c. High risk
d. No risk
6. YU has been diagnosed with having
NSTEMI because on his ECG readings and
cardiac biomarkers. Based on his TIMI score
and risk assessment, he is stratified as being
moderate risk. What initial strategy should
YU undergo for treatment of his NSTEMI?
a. Invasive strategy
b. Conservative strategy
c. No further therapy is needed
d. More information is needed
7. Which of the following laboratory values
should be monitored for a patient treated with
abciximab?
a. Serum creatinine
b. Liver function tests
c. Platelets
d. Troponin
8. Which of the following describes an
advantage of UFH over other anticoagulants
used in ACS patients?
a. Lower incidence of heparin-induced
thrombocytopenia
b. Can be monitored in catheterization lab
with ACT
c. Administration routes include
subcutaneously or intravenously
d. Lower incidence of bleeding compared to
bivalirudin

ANSWER SHEET AND EVALUATION FOR
THIS HOME-STUDY ACTIVITY ARE ON
PAGE 50.
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9. Which of the following is an absolute
contraindication to fibrinolytic therapy?
a. Ischemic stroke within the last 3 months
b. Blood pressure greater than 180/110 mmHg
c. Chronic warfarin therapy
d. Pregnancy
10. A 45 year old male patient weighing 120
kg was admitted to the hospital and diagnosed
with having STEMI. He has a history of
recent gastrointestinal bleeding and is currently
taking omeprazole for it. Which antiplatelet
medication would be best given to initially
treat this patient for his STEMI?
a. ASA		
b. ASA + clopidogrel
c. ASA + prasugrel
d. ASA + ticagrelor
e. None of the above
11. LK is an 80 year old male with a history
of COPD. He is afraid taking medications that
may exacerbate his COPD. He was admitted
to the hospital and was diagnosed with having
STEMI. A PCI was performed and a sirolimus
stent was implanted in his coronary artery.
What medication regimen is appropriate for
this patient upon discharge for maintenance of
his ACS?
a. ASA 325mg daily for 1 months +
clopidogrel 75mg daily for 2 months
b. ASA 325 mg daily for 3 months + ticagrelor
90mg BID for 12 months
c. ASA 325 mg daily for 3 months + prasugrel
10 mg daily for 12 months
d. ASA 325 mg daily for 3 months +
clopidogrel 300mg daily for 12 months
e. ASA 325 mg daily for 3 months + prasugrel
10 mg daily for 3 months
12. A 57 year old male patient who is currently
on eptifibatide, prasugrel, and unfractionated
heparin is about to undergo elective CABG for
his NSTEMI. Which of the following changes
in his drug are appropriate to make prior to his
upcoming procedure?
a. Hold the UFH for at least 2 days
b. Hold the prasugrel for at least 5 days
c. Hold the prasugrel for at least 7 days
d. Hold the eptifibatide for at least 2 hours
e. c and d
13. HT is a 50 year old male patient that was
recently treated at the hospital for his STEMI
and is ready to be discharged. His past medical
history includes hypertension and type 2
diabetes. What medications should HT be
placed on prior to him being discharged for
secondary prevention of ACS?
a. Atorvastatin
b. Aspirin
c. Metoprolol
d. b and c
e. All of the above

